Last data update: Sep 16, 2024. (Total: 47680 publications since 2009)
Records 1-1 (of 1 Records) |
Query Trace: Soriano-Gabarro M [original query] |
---|
Estimating the vaccine-preventable burden of hospitalized pneumonia among young Mozambican children
Roca A , Sigauque B , Quinto L , Morais L , Berenguera A , Corachan M , Ribo JL , Naniche D , Bassat Q , Sacoor Ch , Nhalungo D , Macete E , Schuchat A , Soriano-Gabarro M , Flannery B , Alonso PL . Vaccine 2010 28 (30) 4851-7 Polysaccharide-protein conjugate vaccines against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae have proven efficacy against radiologically confirmed pneumonia. Measurement of pneumonia incidence provides a platform to estimate of the vaccine-preventable burden. Over 24 months, we conducted surveillance for radiologically confirmed severe pneumonia episodes among children <2 years of age admitted to a rural hospital in Manhica, southern Mozambique. Study children were tested for HIV during the second year of surveillance. Severe pneumonia accounted for 15% of 5132 hospital admissions and 32% of in-hospital mortality among children <2 years of age. Also, 43% of chest radiographs were interpreted as radiologically confirmed pneumonia. HIV-infection was associated with 81% of fatal pneumonia episodes among children tested for HIV. The minimum incidence rate of radiologically confirmed pneumonia requiring hospitalization was 19 episodes/1000 child-years. Incidence rates among HIV-infected children were 9.3-19.0-fold higher than HIV-uninfected. Introduction of Hib and pneumococcal conjugate vaccines would have a substantial impact on pneumonia hospitalizations among African children if vaccine effects are similar to those observed in clinical trials. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Sep 16, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure